-
H.C. Wainwright Reiterates Buy Rating on Zentalis Pharmaceuticals (ZNTL)
-
Zentalis Pharmaceuticals, Inc. (ZNTL) Tops Q1 EPS by 1c
-
Stifel Reiterates Buy Rating on Zentalis Pharmaceuticals (ZNTL)
-
H.C. Wainwright Reiterates Buy Rating on Zentalis Pharmaceuticals (ZNTL)
-
Zentalis Pharmaceuticals (ZNTL) Files $250M Mixed Shelf
-
H.C. Wainwright Reiterates Buy Rating on Zentalis Pharmaceuticals (ZNTL)
-
Zentalis Pharmaceuticals (ZNTL) PT Lowered to $10 at H.C. Wainwright
-
Zentalis Pharmaceuticals (ZNTL) PT Lowered to $2.50 at Jefferies
-
Zentalis Pharmaceuticals (ZNTL) PT Lowered to $10 at Oppenheimer
-
Zentalis Pharmaceuticals (ZNTL) Shares Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer
-
Zentalis Pharmaceuticals (ZNTL) Announces Strategic Restructuring to Support Late-Stage Azenosertib Development
-
Zentalis Pharmaceuticals (ZNTL) Announces Management Appointments
-
Zentalis Pharmaceuticals (ZNTL) Announces Executive Leadership Changes
-
TD Cowen Reiterates Buy Rating on Zentalis Pharmaceuticals (ZNTL)
-
Oppenheimer Reiterates Outperform Rating on Zentalis Pharmaceuticals (ZNTL)
-
Zentalis Pharmaceuticals (ZNTL) Announces FDA Lifted Partial Clinical Hold on Azenosertib Studies
-
UBS Downgrades Zentalis Pharmaceuticals (ZNTL) to Neutral
-
Jefferies Downgrades Zentalis Pharmaceuticals (ZNTL) to Hold
-
Morgan Stanley Downgrades Zentalis Pharmaceuticals (ZNTL) to Equalweight
-
Zentalis Pharmaceuticals (ZNTL) PT Lowered to $20 at H.C. Wainwright
-
Zentalis Pharmaceuticals (ZNTL) PT Lowered to $10 at Stifel
-
Wells Fargo Downgrades Zentalis Pharmaceuticals (ZNTL) to Equal Weight
-
Zentalis Pharmaceuticals (ZNTL) Resumes Trading, Down 29%
-
Zentalis Pharmaceuticals (ZNTL) Provides Update on Azenosertib Clinical Development Program

